Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Toxicol Appl Pharmacol ; 278(3): 201-8, 2014 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-24055644

RESUMO

Many xenobiotics have been identified as in vitro androgen receptor (AR) antagonists, but information about their ability to produce combined effects at low concentrations is missing. Such data can reveal whether joint effects at the receptor are induced at low levels and may support the prioritisation of in vivo evaluations and provide orientations for the grouping of anti-androgens in cumulative risk assessment. Combinations of 30 AR antagonists from a wide range of sources and exposure routes (pesticides, antioxidants, parabens, UV-filters, synthetic musks, bisphenol-A, benzo(a)pyrene, perfluorooctane sulfonate and pentabromodiphenyl ether) were tested using a reporter gene assay (MDA-kb2). Chemicals were combined at three mixture ratios, equivalent to single components' effect concentrations that inhibit the action of dihydrotesterone by 1%, 10% or 20%. Concentration addition (CA) and independent action were used to calculate additivity expectations. We observed complete suppression of dihydrotestosterone effects when chemicals were combined at individual concentrations eliciting 1%, 10% or 20% AR antagonistic effect. Due to the large number of mixture components, the combined AR antagonistic effects occurred at very low concentrations of individual mixture components. CA slightly underestimated the combined effects at all mixture ratios. In conclusion, large numbers of AR antagonists from a wide variety of sources and exposure routes have the ability of acting together at the receptor to produce joint effects at very low concentrations. Significant mixture effects are observed when chemicals are combined at concentrations that individually do not induce observable AR antagonistic effects. Cumulative risk assessment for AR antagonists should apply grouping criteria based on effects where data are available, rather than on criteria of chemical similarity.


Assuntos
Antioxidantes/toxicidade , Interações Medicamentosas , Disruptores Endócrinos/toxicidade , Poluentes Ambientais/toxicidade , Modelos Biológicos , Drogas Antiandrogênicas não Esteroides/toxicidade , Praguicidas/toxicidade , Androgênios/química , Androgênios/farmacologia , Linhagem Celular Tumoral , Qualidade de Produtos para o Consumidor , Di-Hidrotestosterona/antagonistas & inibidores , Di-Hidrotestosterona/farmacologia , Genes Reporter/efeitos dos fármacos , Humanos , Resíduos Industriais/efeitos adversos , Concentração Osmolar , Regiões Promotoras Genéticas/efeitos dos fármacos , Receptores Androgênicos/química , Receptores Androgênicos/genética , Receptores Androgênicos/metabolismo , Proteínas Recombinantes de Fusão/metabolismo , Elementos de Resposta/efeitos dos fármacos , Medição de Risco/métodos
2.
Chemosphere ; 349: 140773, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38000554

RESUMO

Although the herbicide linuron is banned for use in the EU due to its reproductive and developmental toxicity, it can still be found in randomly sampled foods grown in and outside the EU. It is not clear if metabolites of linuron can contribute to the endocrine disrupting effects following exposure to the parent compound. To address this gap, we analysed linuron and the metabolites 1-(3,4-dichlorophenyl) urea (DCU), 3,4-dichloroaniline (DCA) and 1-(3,4-dichlorophenyl)-3-methoxyurea (DCXU) for androgen receptor (AR) activities and effects on steroidogenesis. Generally, linuron and the metabolites showed qualitatively similar antiandrogenic profiles, but potencies varied. All compounds were AR antagonists, with linuron showing highest potency (IC50 of 2.8 µM). The overall picture of effects on steroidogenesis showed that linuron and metabolites increased the levels of estrogens and corticosteroids, whereas the synthesis of androgens was inhibited. The metabolite DCU was by far the most potent inhibitor of testosterone synthesis (IC50 of 6.7 µM compared to IC50 of 51.1 µM for linuron). We suggest that it is likely that the metabolites contribute to the antiandrogenic effects of linuron in vivo, especially by inhibiting testosterone synthesis.


Assuntos
Herbicidas , Linurona , Linurona/toxicidade , Herbicidas/toxicidade , Androgênios , Antagonistas de Androgênios/toxicidade , Testosterona
3.
Reprod Toxicol ; 128: 108662, 2024 09.
Artigo em Inglês | MEDLINE | ID: mdl-38986849

RESUMO

The Adverse Outcome Pathway (AOP) framework has gained widespread acceptance in toxicological disciplines as a tool for aiding chemical hazard assessment. Despite increased activity in AOP development, progress towards a high volume of fully endorsed AOPs has been slow, partly due to the challenging task of constructing complete AOPs according to the AOP Developer's Handbook. To facilitate greater uptake of new knowledge units onto the open-source AOP-wiki platform, a pragmatic approach was recently proposed. This approach involves considering Key Event Relationships (KERs) for individual development through systematic approaches, as they represent essential units of knowledge from which causality can be inferred; from low complexity test data to adverse outcomes in intact organisms. However, more broadly adopted harmonized methodologies for KER development would be desirable. Using the AOP Developer's Handbook as a guide, a KER linking 'decreased androgen receptor (AR) activity' with 'reduced anogenital distance (AGD)' was developed to demonstrate a methodology applicable for future developments of KERs requiring systematic literature retrieval approaches.


Assuntos
Rotas de Resultados Adversos , Receptores Androgênicos , Receptores Androgênicos/metabolismo , Humanos , Animais , Masculino , Feminino , Canal Anal/anatomia & histologia , Canal Anal/efeitos dos fármacos , Medição de Risco , Genitália/anatomia & histologia , Genitália/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA